Australia's Neuren Pharmaceuticals gains on upbeat FY trofinetide earnings outlook
BUZZ-Australia's Neuren Pharmaceuticals gains on upbeat FY trofinetide earnings outlook ** Shares of Australia's Neuren Pharmaceuticals NEU.AX climb as much as 17.7% to A$23.3, marking their biggest intraday pct gain since June 29
** Shares hit their highest level since August 20
** Biopharmaceutical co upgrades 2026 income forecast from trofinetide (DAYBUE) to $91 million-$93 million from $53 million-$56 million. Trofinetide is used for the treatment of Rett Syndrome, a genetic neurological and developmental disorder
** Co says partner Acadia Pharmaceuticals raised full-year global sales forecast for DAYBUE to $505 million-$520 million from $480 million-$510 million
** Adds Q3 DAYBUE net sales rose 39% year-on-year to $140 million
** Adds Japan results of Phase 3 trial of DAYBUE support a planned regulatory filing in 2027 and potential launch in 2028
** More than 790,000 shares change hands, about 2.3x the 30-day average
** YTD, stock up 23.6%
(Reporting by Subhalakshmi Dey in Bengaluru)
Recent news on Neuren Pharmaceuticals
See all newsAustralia's Neuren set for weekly gain on FDA nod, drug forecast upgrade
Australia's Neuren Pharmaceuticals gains on upbeat FY trofinetide earnings outlook
Australia's Neuren Pharma rises as US FDA grants orphan tag for NNZ-2591
Strong partner sales propel Neuren Pharmaceuticals to top of Australia benchmark
Brief: Neuren Pharmaceuticals Says DAYBU Recommended For Approval In European Union